ponatinib efficacy and safety with the t315i mutation: long-term follow-up of phase 1&2 trials
Published 9 years ago • 148 plays • Length 4:18Download video MP4
Download video MP3
Similar videos
-
1:54
targeting the t315i mutation with ponatinib to treat patients with r/r ph all
-
5:07
case 2: ponatinib for t315i-mutated cml
-
1:35
long-term follow-up from the oiti trial: ponatinib in patients with cml in italy
-
2:55
what are the efficacy and safety considerations in using ponatinib?
-
4:44
ponatinib in chronic-phase cml patients with prior second generation tki exposure
-
3:20
case 1: ponatinib in chronic-phase cml
-
1:38
an update on the optic study: adjusting the dose of ponatinib for cp-cml
-
5:04
long-term follow-up of the cartitude-4 trial: improved os & pfs with cilta-cel in r/r myeloma
-
1:57
post-hoc analysis of optic: patient responses to ponatinib by t315i mutational status
-
5:22
bosutinib versus ponatinib in r/r cml
-
1:17
ponatinib versus ascimininib in the third-line treatment of cml
-
1:54
five-year follow-up data from the bfore trial: bosutinib versus imatinib in cml
-
1:43
dosing strategy of ponatinib in cp-cml: insights from the optic trial
-
3:04
ponatinib is superior to imatinib in combination with chemotherapy for patients with newly diagn...
-
2:49
outcomes of patients with cml-cp treated with ponatinib vs 2g-tkis in the third-line setting
-
1:57:54
mpn clinical trials 101
-
1:08
managing drug resistance in cp-cml with ponatinib and asciminib
-
1:26:42
webinar for patient advocates: management of iclusig in the clinical setting
-
1:01:58
clinical trials 101